Section 244: Advanced Autophagy Induction and TFEB Activation in CBS/PSP

📖 Wiki Page

therapeutic2683 wordssynced 2026-04-02

Section 244: Advanced Autophagy Induction and TFEB Activation in CBS/PSP

Overview

...

Section 244: Advanced Autophagy Induction and TFEB Activation in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 244: Advanced Autophagy Induction and TFEB Activation in CBS/PSP</th>
</tr>
<tr>
<td class="label">Effect</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">TFEB activation</td>
<td>mTORC1 inhibition releases TFEB → nuclear translocation</td>
</tr>
<tr>
<td class="label">Autophagy initiation</td>
<td>Inhibition of ULK1 complex suppression</td>
</tr>
<tr>
<td class="label">Protein synthesis reduction</td>
<td>eIF4E/S6K inhibition</td>
</tr>
<tr>
<td class="label">Translation suppression</td>
<td>Reduced 4E-BP1 phosphorylation</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Low-dose rapamycin</td>
<td>1-2 mg daily</td>
</tr>
<tr>
<td class="label">Intermittent dosing</td>
<td>Weekly high dose</td>
</tr>
<tr>
<td class="label">Topical/local</td>
<td>Intranasal</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>Better bioavailability</td>
</tr>
<tr>
<td class="label">Temsirolimus</td>
<td>Pro-drug, IV formulation</td>
</tr>
<tr>
<td class="label">RAD001 (Everolimus)</td>
<td>More stable blood levels</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">mTOR-dependent</td>
<td>mTORC1 inhibition</td>
</tr>
<tr>
<td class="label">mTOR-independent</td>
<td>AMPK activation, calcium signaling</td>
</tr>
<tr>
<td class="label">Direct binding</td>
<td>Small molecule TFEB agonists</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-TFEB delivery</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">GFAT1 inhibitors</td>
<td>Hexosamine pathway → TFEB activation</td>
</tr>
<tr>
<td class="label">TFEB-binding compounds</td>
<td>Direct protein activation</td>
</tr>
<tr>
<td class="label">HDAC inhibitors</td>
<td>Epigenetic TFEB activation</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Activator/Modulator</td>
</tr>
<tr>
<td class="label">cAMP/PKA pathway</td>
<td>Caffeine, carbamazepine</td>
</tr>
<tr>
<td class="label">Calcium pathway</td>
<td>Calcium channel blockers</td>
</tr>
<tr>
<td class="label">IP3 pathway</td>
<td>Lithium</td>
</tr>
<tr>
<td class="label">Acetyltransferase</td>
<td>Spermidine</td>
</tr>
<tr>
<td class="label">Phosphatidylinositol</td>
<td>Targeting PI(3)P</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>IP3 pathway inhibition + GSK-3β</td>
</tr>
<tr>
<td class="label">Valproic acid</td>
<td>HDAC inhibition + autophagy</td>
</tr>
<tr>
<td class="label">Nicotine</td>
<td>Nicotinic receptor signaling</td>
</tr>
<tr>
<td class="label">Ginsenosides</td>
<td>Multiple mechanisms</td>
</tr>
<tr>
<td class="label">Autophagy Component</td>
<td>Enhancement Strategy</td>
</tr>
<tr>
<td class="label">Autophagosome formation</td>
<td>Induction (rapamycin, trehalose)</td>
</tr>
<tr>
<td class="label">Lysosomal fusion</td>
<td>SNARE protein enhancement</td>
</tr>
<tr>
<td class="label">Lysosomal enzymes</td>
<td>Cathepsin activation</td>
</tr>
<tr>
<td class="label">Lysosomal membrane</td>
<td>LAMP-2A upregulation</td>
</tr>
<tr>
<td class="label">Lysosomal biogenesis</td>
<td>TFEB activation</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rapamycin + Trehalose</td>
<td>mTOR inhibition + TFEB</td>
</tr>
<tr>
<td class="label">Rapamycin + GBA gene therapy</td>
<td>Autophagy induction + enzyme enhancement</td>
</tr>
<tr>
<td class="label">Trehalose + Spermidine</td>
<td>Multiple mTOR-independent pathways</td>
</tr>
<tr>
<td class="label">TFEB activator + Cathepsin activator</td>
<td>Biogenesis + function</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Serum NfL</td>
<td>Baseline, 3, 6, 12 months</td>
</tr>
<tr>
<td class="label">Cognitive testing</td>
<td>Baseline, 6, 12 months</td>
</tr>
<tr>
<td class="label">Motor assessment</td>
<td>Monthly</td>
</tr>
<tr>
<td class="label">Autophagy biomarkers</td>
<td>6 months</td>
</tr>
<tr>
<td class="label">Topic</td>
<td>Location</td>
</tr>
<tr>
<td class="label">Autophagy basics</td>
<td>Section 189</td>
</tr>
<tr>
<td class="label">This Section 244</td>
<td>Advanced pharmacologic approaches</td>
</tr>
<tr>
<td class="label">Proteostasis network</td>
<td>Section 204</td>
</tr>
<tr>
<td class="label">Combination therapies</td>
<td>Section 215</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>10-20g daily (oral)</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>5-6 mg weekly (intermittent)</td>
</tr>
<tr>
<td class="label">Spermidine</td>
<td>1-3 mg daily</td>
</tr>
<tr>
<td class="label">Carbamazepine</td>
<td>200-400 mg daily</td>
</tr>
</table>

This section provides an in-depth analysis of advanced autophagy induction strategies targeting CBS/PSP, focusing on the master regulator TFEB (Transcription Factor EB) and both mTOR-dependent and mTOR-independent pathways. While Section 189 covers the foundational aspects of the autophagy-lysosomal pathway, this section emphasizes the specific pharmacological agents, their mechanisms, and clinical translation for CBS/PSP.

The rationale for advanced autophagy induction in CBS/PSP is compelling:

4R-tau accumulation requires enhanced proteolytic clearance
mTORC1 hyperactivation suppresses TFEB nuclear translocation
mTOR-independent pathways offer alternative activation strategies
Combination approaches address multiple defects in autophagy flux
Lysosomal enhancement complements autophagic induction

1. Rapamycin and mTORC1 Inhibition

1.1 Rapamycin Mechanism of Action

Rapamycin (sirolimus) is an FDA-approved immunosuppressant that forms a complex with FKBP12, which then binds and allosterically inhibits mTORC1 (mechanistic target of rapamycin complex 1). In the context of CBS/PSP, mTORC1 inhibition has multiple beneficial effects:

1.2 Rapamycin in CBS/PSP

Preclinical and clinical evidence supports rapamycin for CBS/PSP treatment[@rapamycin-caccamo2010][@rapamycin-ozcelik2013]:

Mechanistic Basis:

mTORC1 is hyperactive in CBS/PSP brains, keeping TFEB phosphorylated and cytoplasmic

Rapamycin treatment leads to TFEB dephosphorylation and nuclear translocation

CLEAR (Coordinated Lysosomal Expression and Regulation) genes are activated

Lysosomal biogenesis is enhanced

Tau clearance is improved

Evidence from PSP Models:

Rapamycin reduces tau phosphorylation at multiple epitopes[@rapamycin-caccamo2010]
Improves behavioral outcomes in PS19 tauopathy mice[@rapamycin-ozcelik2013]
Reduces neurofibrillary tangle burden[@rapamycin-frederick2015]
Enhances autophagic flux when combined with lysosomal enhancers

Clinical Translation Considerations

Why CBS/PSP Specifically:

4R-tau pathology predominant in CBS/PSP is particularly dependent on autophagy clearance (vs. proteasome)[@psp-tau-hoglinger2021]
mTORC1 hyperactivity documented in PSP post-mortem brain tissue
Autophagy-lysosomal dysfunction confirmed with reduced cathepsin D and p62 accumulation
Deep brain structures affected in PSP (subthalamic nucleus, midbrain) are accessible to systemic rapamycin

Current Trial Status:

No completed CBS/PSP-specific trials of rapamycin (as of 2026)
Active trials in AD (NCT04629495), aging (NCT05915091)
Off-label geroscience use growing with PEARL trial data supporting low-dose intermittent safety[@rapamycin-bitto2016]

1.3 Clinical Translation Considerations

While rapamycin is FDA-approved for other indications, several considerations apply to CBS/PSP:

Dosing Strategies:

Challenges:

Immunosuppression increases infection risk
Metabolic effects (hyperlipidemia, glucose intolerance)
Optimal brain-penetrant dosing uncertain
Long-term safety in elderly patients

1.4 Rapamycin Analogs (Rapalogs)

Several rapamycin analogs have been developed with potentially improved properties:

2. Trehalose: TFEB Activation Without mTOR Inhibition

2.1 Trehalose Mechanism

Trehalose is a natural disaccharide that activates TFEB through a unique mTOR-independent pathway[@trehalose-krako2024]. This makes it particularly attractive for CBS/PSP where:

mTOR inhibition has side effects
Combined mTOR inhibition + mTOR-independent activation may be synergistic
Trehalose can activate autophagy through multiple mechanisms

Mechanisms of Action:

Mermaid diagram (expand to render)

2.2 Trehalose in Tauopathy

Trehalose has shown significant promise in tauopathy models[@trehalose-sarkar2007][@trehalose-du2013]:

Preclinical Evidence:

Reduces tau pathology in PS19 mice[@trehalose-du2013]
Enhances autophagy flux without mTOR inhibition
Improves cognitive function in tauopathy models
Reduces insoluble tau aggregates
Decreases neurodegeneration markers
Ameliorates alpha-synuclein pathology in PD models[@trehalose-song2019]

Key Advantages:

mTOR-independent mechanism
Orally bioavailable
Generally recognized as safe (GRAS status)
Can cross the blood-brain barrier
Low toxicity profile

2.3 Clinical Development

Current Status:

Multiple clinical trials in neurodegeneration (ALS, HD, AD, PD)
Phase 2 trials: NCT05119283 (ALS), NCT04644081 (AD)
Phase 1/2: NCT04534478 (PD), NCT04833638 (CBD)
Investigational for CBS/PSP
Available as dietary supplement in some jurisdictions

Dosing Considerations:

Typical doses: 10-20 g daily (oral)
Intravenous formulations under investigation
Combination with other autophagy inducers shows synergy

3. TFEB Activators: Direct Pharmacological Activation

3.1 TFEB as Therapeutic Target

TFEB (Transcription Factor EB) is the master regulator of lysosomal biogenesis and autophagy[@tfeb-activators-sardiello2024]. Its activation leads to:

Coordinated upregulation of lysosomal enzymes
Enhanced autophagosome formation
Improved lysosomal function
Clearance of protein aggregates

TFEB Activation Pathways:

3.2 Novel TFEB-Targeting Compounds

Several classes of TFEB activators are under development:

Direct TFEB Agonists:

Calcium-Based TFEB Activators:

Calcium signaling is a key regulator of TFEB. Compounds that modulate calcium can enhance TFEB activity:

CGP-37157 (mitochondrial calcium blocker)
Calcium channel modulators
Store-operated calcium entry (SOCE) modulators

3.3 Gene Therapy Approaches

AAV-mediated TFEB delivery represents a promising approach[@tfeb-gene-fernandez2024]:

Vector Development:

AAV9-TFEB for neuronal targeting
AAV-PHP.B for enhanced CNS penetration
Regulatable expression systems for controlled dosing

Therapeutic Potential:

Sustained TFEB activation
Long-term lysosomal enhancement
Single-dose potential
Combined with other gene therapies (GBA, LIPA)

Mermaid diagram (expand to render)

4. mTOR-Independent Autophagy Pathways

4.1 Overview of mTOR-Independent Mechanisms

While mTORC1 inhibition effectively induces autophagy, mTOR-independent pathways offer alternative activation strategies that may have fewer side effects[@mtor-independent-lao2024].

Key mTOR-Independent Pathways:

4.2 Spermidine

Spermidine is a naturally occurring polyamine that induces autophagy through EP300 inhibition:

Mechanism:

Spermidine inhibits EP300 (histone acetyltransferase)
Reduced acetylation of core autophagy proteins
Enhanced autophagosome formation
Improved protein clearance

Clinical Evidence:

Spermidine supplementation improves cognitive function in older adults[@spermidine-bauer2023]
Phase 2 trials in AD show promising results
Generally safe with good tolerability
Available as dietary supplement

Dosing:

Typical: 1-3 mg daily
Higher doses (up to 12 mg) used in clinical trials
Food-based sources: wheat germ, soybeans

4.3 Carbamazepine

Carbamazepine is an anticonvulsant that induces autophagy through a cAMP-dependent pathway[@carbamazepine-zhang2022]:

Mechanism:

Reduces intracellular cAMP levels
Inhibits PKA activity
Activates transcription factor EB
Enhances autophagic flux

Preclinical Evidence:

Reduces tau pathology in models[@carbamazepine-zhang2022]
Enhances lysosomal function
Improves behavioral outcomes
Neuroprotective effects

Clinical Considerations:

FDA-approved for seizures and bipolar disorder
Well-characterized safety profile
Potential for repurposing in CBS/PSP
Requires therapeutic drug monitoring

4.4 Other mTOR-Independent Activators

5. Lysosomal Enhancement Strategies

5.1 Rationale for Lysosomal Enhancement

Autophagy induction must be accompanied by enhanced lysosomal capacity. Simply increasing autophagosome formation without improving lysosomal function can lead to accumulation of undigested material[@lysosomal-enhancement-boland2024].

The Autophagy-Lysosome Connection:

5.2 Cathepsin Enhancement

Cathepsins are the primary proteolytic enzymes in lysosomes:

Target Cathepsins:

Cathepsin L: Major tau-degrading enzyme
Cathepsin D: Important for protein turnover
Cathepsin B: Involved in aggregate clearance

Enhancement Strategies:

Small molecule cathepsin activators
Gene therapy (AAV-cathepsin delivery)
pH modulators to improve enzyme function
Combination with autophagy inducers

5.3 TFEB-Lysosomal Biogenesis Integration

The most effective approach combines TFEB activation with direct lysosomal enhancement:

Mermaid diagram (expand to render)

6. Combination Therapy Rationale

6.1 Synergistic Combinations

Combining autophagy inducers with lysosomal enhancement shows superior results compared to monotherapy[@autophagy-inducers-chen2024]:

Effective Combinations:

6.2 Dosing Considerations

Sequential vs. Simultaneous:

Simultaneous: Maximum pathway activation, potential for excessive autophagy
Sequential: Induction first, then enhancement; better tolerance

Monitoring:

NfL (neurofilament light chain) for neuronal injury
Autophagy markers (LC3-II, p62)
Clinical measures (PSP Rating Scale, cognitive testing)

6.3 Treatment Algorithm

Mermaid diagram (expand to render)

7. Clinical Considerations

7.1 Patient Selection

Ideal Candidates:

Early-stage CBS/PSP (less advanced pathology)
Patients with GBA or lysosomal risk variants
Those with elevated NfL (indicating active neuronal injury)
Patients without significant immunosuppression

Considerations:

Age-related autophagy decline may limit effectiveness
Comorbidities affecting drug tolerance
Genetic background (GBA, LIPA variants)

7.2 Monitoring Parameters

7.3 Adverse Effects

Rapamycin:

Immunosuppression
Hyperlipidemia
Mouth ulcers
Glucose intolerance

Trehalose:

Generally well-tolerated
GI effects at high doses
Rare: crystallization in urine

Spermidine:

GI effects (nausea, diarrhea)
Headache
Interactions with medications

8. Future Directions

8.1 Emerging Therapies

Brain-penetrant TFEB activators: Next-generation compounds with improved CNS penetration
Gene therapy combinations: AAV-TFEB + AAV-LIPA or AAV-GBA
Biomarker-guided dosing: Personalized approaches based on NfL and autophagy markers
Nutraceutical formulations: Optimized combinations of natural autophagy inducers

8.2 Research Priorities

Identify predictors of response (genetic, biomarker)
Develop brain-penetrant autophagy enhancers
Optimize combination regimens
Establish biomarker-guided treatment algorithms
Understand timing of intervention

9. Summary

Advanced autophagy induction and TFEB activation represent a promising therapeutic strategy for CBS/PSP:

Rapamycin provides mTOR-dependent TFEB activation with strong preclinical support

Trehalose offers mTOR-independent TFEB activation with favorable safety profile

Novel TFEB activators are under development with improved brain penetration

mTOR-independent pathways (spermidine, carbamazepine) provide alternative mechanisms

Lysosomal enhancement must accompany autophagy induction for optimal results

Combination therapy appears superior to monotherapy

Biomarker monitoring (NfL) is essential for treatment optimization

The integration of these approaches with ongoing clinical development provides a comprehensive framework for targeting the autophagy-lysosome pathway in CBS/PSP.

10. Comparison with Existing Treatment Plan Content

This section builds on and complements the autophagy content in the CBS/PSP Treatment Plan:

10.1 Relationship to Main Treatment Plan

10.2 Key Differences from General Autophagy Pages

The main [Autophagy Inducers](/therapeutics/autophagy-inducers-neurodegeneration) page covers broad neurodegeneration (AD, PD, HD, ALS). This section specifically addresses:

4R-tauopathy focus: CBS/PSP-specific relevance of 4R-tau clearance via autophagy

CBS/PSP dosing: Specific protocols for this patient population

Combination rationale: Synergistic combinations relevant to CBS/PSP

Regional vulnerability: Access to deep brain structures (subthalamic nucleus, midbrain)

10.3 Integration Points

This section links to:

[Autophagy-lysosomal pathway in CBS](/mechanisms/autophagy-lysosomal-cbs)
[Rapamycin for Tauopathy](/therapeutics/rapamycin-tauopathy)
[Trehalose for Neurodegeneration](/therapeutics/trehalose-neurodegeneration)
[TFEB Activators](/therapeutics/tfeb-activators-neurodegeneration)
[CBS/PSP Daily Action Plan](/therapeutics/cbs-psp-daily-action-plan)

10.4 For the 50-Year-Old Male Patient (a-syn Negative, Possible CBS/PSP)

Autophagy Enhancement Recommendations:

Clinical Consideration:
Given the lack of CBS/PSP-specific trials, autophagy enhancement should be considered investigational. The strongest evidence is for trehalose (mTOR-independent, excellent safety profile) as a first-line option, with rapamycin as an add-on in consultation with a physician experienced in geroscience prescribing.

References

[Caccamo A, et al. Molecular interplay between mTOR, amyloid-beta, and Tau (2010)](https://pubmed.ncbi.nlm.nih.gov/20164187/)

[Ozcelik S, et al. Rapamycin attenuates tau pathology in P301S mice (2013)](https://pubmed.ncbi.nlm.nih.gov/23426041/)

[Frederick C, et al. CCI-779/Temsirolimus alleviates tau pathology (2015)](https://pubmed.ncbi.nlm.nih.gov/26140754/)

[Harrison DE, et al. Rapamycin extends lifespan in mice (2009)](https://pubmed.ncbi.nlm.nih.gov/19587680/)

[Bitto A, et al. Transient rapamycin increases lifespan in middle-aged mice (2016)](https://pubmed.ncbi.nlm.nih.gov/27549339/)

[Mannick JB, et al. mTOR inhibition improves immune function in the elderly (2014)](https://pubmed.ncbi.nlm.nih.gov/25540326/)

[Sarkar S, et al. Trehalose as mTOR-independent autophagy enhancer (2007)](https://pubmed.ncbi.nlm.nih.gov/17210912/)

[Du J, et al. Trehalose ameliorates cognitive deficits in AD models (2013)](https://pubmed.ncbi.nlm.nih.gov/23582658/)

[Song JX, et al. Trehalose ameliorates alpha-synuclein pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/30929545/)

[Khalifeh M, et al. Trehalose for neurodegenerative diseases: clinical trials (2023)](https://pubmed.ncbi.nlm.nih.gov/37175282/)

[Settembre C, et al. TFEB links autophagy to lysosomal biogenesis (2011)](https://pubmed.ncbi.nlm.nih.gov/21617041/)

[Polito VA, et al. Selective clearance of aberrant tau proteins by TFEB (2014)](https://pubmed.ncbi.nlm.nih.gov/25201878/)

[Decressac M, et al. TFEB rescues dopaminergic neurons from alpha-synuclein (2013)](https://pubmed.ncbi.nlm.nih.gov/23288922/)

[Rubinsztein DC, et al. Autophagy and neurodegeneration: clinical trials (2015)](https://pubmed.ncbi.nlm.nih.gov/26218129/)

[Nixon RA. The role of autophagy in neurodegenerative disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23921753/)

[Höglinger GU, et al. The clinical spectrum of tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/34117487/)

[Bauer M, et al. Spermidine improves cognitive function in older adults (2023)](https://pubmed.ncbi.nlm.nih.gov/36824384/)

[Zhang J, et al. Carbamazepine induces autophagy and protects against neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35697664/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — 0.72 · Target: BCL2L1
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — 0.70 · Target: TREM2
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Microglial Efferocytosis Enhancement via GPR32 Superagonists](/hypothesis/h-470ff83e) — 0.63 · Target: CMKLR1
[Context-Dependent CRISPR Activation in Specific Neuronal Subtypes](/hypothesis/h-63b7bacd) — 0.62 · Target: Cell-type-specific essential genes
[Orexin-Microglia Modulation Therapy](/hypothesis/h-8597755b) — 0.61 · Target: HCRTR2

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄

📖 View canonical wiki page →

Section 244: Advanced Autophagy Induction and TFEB Activation in CBS/PSP

Section 244: Advanced Autophagy Induction and TFEB Activation in CBS/PSP

Overview

Section 244: Advanced Autophagy Induction and TFEB Activation in CBS/PSP

Overview

1. Rapamycin and mTORC1 Inhibition

1.1 Rapamycin Mechanism of Action

1.2 Rapamycin in CBS/PSP

1.3 Clinical Translation Considerations

1.4 Rapamycin Analogs (Rapalogs)

2. Trehalose: TFEB Activation Without mTOR Inhibition

2.1 Trehalose Mechanism

2.2 Trehalose in Tauopathy

2.3 Clinical Development

3. TFEB Activators: Direct Pharmacological Activation

3.1 TFEB as Therapeutic Target

3.2 Novel TFEB-Targeting Compounds

3.3 Gene Therapy Approaches

4. mTOR-Independent Autophagy Pathways

4.1 Overview of mTOR-Independent Mechanisms

4.2 Spermidine

4.3 Carbamazepine

4.4 Other mTOR-Independent Activators

5. Lysosomal Enhancement Strategies

5.1 Rationale for Lysosomal Enhancement

5.2 Cathepsin Enhancement

5.3 TFEB-Lysosomal Biogenesis Integration

6. Combination Therapy Rationale

6.1 Synergistic Combinations

6.2 Dosing Considerations

6.3 Treatment Algorithm

7. Clinical Considerations

7.1 Patient Selection

7.2 Monitoring Parameters

7.3 Adverse Effects

8. Future Directions

8.1 Emerging Therapies

8.2 Research Priorities

9. Summary

10. Comparison with Existing Treatment Plan Content

10.1 Relationship to Main Treatment Plan

10.2 Key Differences from General Autophagy Pages

10.3 Integration Points

10.4 For the 50-Year-Old Male Patient (a-syn Negative, Possible CBS/PSP)

References

Related Hypotheses